Investment
Features
FeesSafety
Academy
More
Pluang+

XRP Ledger updates lending protocol with patch before original version gains validator approval

Protocol Fundamentals
19 Oct 2026
Crypto Briefing
View Source
Neutral
XRP Ledger updates lending protocol with patch before original version gains validator approval

The XRP Ledger has released a patch called LendingProtocolV1_1 to fix its uncollateralized lending system ahead of the original protocol's approval by validators. This update introduces closed-ended vaults for fixed-term loans and changes accounting to a cash basis, recognizing interest only when paid. Despite these improvements, the lending amendments still lack enough validator votes for activation, needing about 29 out of 36 votes but currently holding 19-21. The patch highlights ongoing efforts to refine the lending system, but no clear launch date is set until validator consensus is reached.

The XRP Ledger's lending protocol update is the subject, with Pluang market data providing context. For readers following major cryptocurrencies, 46 of 50 rose and 3 fell today. Notable moves include SXP down 46.27% at Rp37, BAT up 17.84% at Rp3.556 with a typical hold time of 93 days, and BAL up 11.14% at Rp16.297 as of Oct 20, 2026 03:42 WIB.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
30 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
30 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App